A drawback of RpL7/L12 is the conserved nature within the bacterial kingdom and significant cross-reactivity resulting in significant overlap in serum from healthy controls and CRC patients (Boleij et al., 2010). This evidence concerns the gene RPL7 and colorectal carcinoma.